Price · as of 2024-12-31
—
Market cap 7.22B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.44 | — |
| Intrinsic Value(DCF) | $21.74 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $12.07 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $30.02 | $32.85 | $0.68 | $0.00 | $0.00 |
| 2017 | $19.67 | $105.63 | $172,060.39 | $0.00 | $0.00 |
| 2018 | $13.56 | $40.41 | $12,482.21 | $0.00 | $0.00 |
| 2019 | $17.39 | $25.50 | $38.45 | $0.00 | $16.89 |
| 2020 | $22.91 | $26.96 | $3.30 | $0.00 | $7.09 |
| 2021 | $27.19 | $42.55 | $10.83 | $0.59 | $0.00 |
| 2022 | $18.50 | $19.94 | $2.16 | $0.00 | $3.91 |
| 2023 | $46.55 | $36.77 | $4.04 | $0.00 | $0.00 |
| 2024 | $46.07 | $35.44 | $5.47 | $0.00 | $12.07 |
AI valuation
Our deep-learning model estimates Merus N.V.'s (MRUS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.44
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$21.74
— upside
Graham-Dodd
—
— upside
Graham Formula
$12.07
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MRUS | Merus N.V. | $95.18 | 7.22B | -63% | -77% | — | -87% | -13.74 | 4.57 | 84.83 | -9.34 | -117.77 | 4.58 | 37.15% | -752.96% | -595.93% | -42.88% | -391.57% | -34.71% | 0.02 | — | 6.54 | 6.22 | 1.09 | 1167.00% | -1238.00% | 2826.00% | -6.34% | -2.13 | -279.56% | 0.00% | 0.00% | 3.06% | -9.26 | -12.97 | 69.71 | 11.12 |
| ABVX | Abivax S.A. | $99.61 | 7.53B | -59% | -97% | — | — | -2.42 | 10.50 | 39.48 | -2.21 | — | 27.39 | 100.00% | -1602.89% | -1633.08% | -148.98% | 2618.19% | -66.22% | 2.40 | -41.33 | 1.84 | 1.72 | 0.27 | -1837.00% | 13354.00% | 5429.00% | -36.31% | -1.66 | 2341.68% | 0.00% | 0.00% | 0.00% | -2.19 | -2.45 | 35.14 | -3.71 |
| AXSM | Axsome Therapeutics, Inc. | $135.69 | 6.84B | -26% | +10,301% | — | — | -45.19 | 93.74 | 12.96 | -48.76 | — | 231.63 | 92.56% | -26.51% | -28.69% | -252.11% | 574.69% | -29.11% | 2.73 | -25.81 | 1.55 | 1.44 | 0.49 | -3856.00% | 6555.00% | -2741.00% | -1.13% | -0.25 | 318.10% | 0.00% | 0.00% | 0.00% | -48.43 | -87.74 | 12.84 | 6.09 |
| CORT | Corcept Therapeutics Inco… | $76.65 | 8.08B | +39% | -24% | -86% | -74% | 38.06 | 5.77 | 4.91 | 49.30 | — | 5.77 | 98.30% | 5.88% | 13.09% | 14.79% | 15.32% | 11.71% | 0.01 | — | 2.92 | 2.60 | -1.67 | -3333.00% | 1279.00% | -2762.00% | 3.80% | 0.85 | 48.48% | 0.00% | 0.00% | 6.58% | 75.23 | 23.77 | 4.43 | 14.49 |
| CYTK | Cytokinetics, Incorporate… | $59.19 | 7.08B | +1% | -58% | — | — | -9.39 | -11.18 | 83.75 | -10.03 | -38.60 | -11.18 | 100.00% | -695.44% | -891.60% | 197.47% | 179.99% | -55.55% | -1.95 | — | 4.53 | 4.36 | -0.52 | 2433.00% | 37656.00% | 3377.00% | -7.25% | -2.52 | 157.23% | 0.00% | 0.00% | 3.96% | -12.70 | -14.54 | 88.31 | -2.06 |
| HALO | Halozyme Therapeutics, In… | $68.30 | 8.03B | +28% | +73% | -87% | +71% | 26.42 | 171.48 | 5.99 | 9.10 | — | -5.53 | 78.13% | 58.45% | 22.69% | 153.59% | 93.94% | 13.81% | 0.00 | 45.03 | 4.66 | 3.30 | -0.15 | -2536.00% | 3755.00% | 3762.00% | 7.70% | 3.68 | 109.29% | 0.00% | 0.00% | 22.29% | 10.08 | 12.76 | 5.89 | 3.99 |
| JAZZ | Jazz Pharmaceuticals plc | $137.22 | 8.32B | +32% | -39% | -92% | — | -32.61 | 2.69 | 2.72 | 104.22 | — | -5.99 | 88.21% | 5.26% | -8.35% | -8.47% | 2.26% | -3.01% | 0.25 | 1.15 | 1.86 | 0.99 | -2.87 | -16751.00% | 488.00% | -377.00% | 11.17% | 0.60 | 23.02% | 0.00% | 0.00% | 36.04% | 50.37 | 8.72 | 2.65 | 1.65 |
| MTSR | Metsera, Inc. | $71.38 | 7.5B | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -108.40% | 1345.61% | -67.48% | 0.03 | -1008.22 | 5.34 | 5.24 | 1.57 | 10947.00% | — | 18254.00% | — | -1.49 | 625.73% | — | 0.00% | — | — | — | — | — |
| NUVL | Nuvalent, Inc. | $92.09 | 6.7B | — | — | — | — | -17.31 | 5.90 | — | -571.33 | -35.43 | 5.90 | 0.00% | — | — | -36.70% | 481.41% | -33.30% | 0.00 | — | 15.27 | 15.05 | 24.96 | 4885.00% | — | 4871.00% | -3.74% | -3.02 | 319.78% | 0.00% | 0.00% | 1.58% | -14.46 | -21.77 | — | 26.05 |
| RNA | Avidity Biosciences, Inc. | $69.80 | 8.98B | -69% | -86% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
| RYTM | Rhythm Pharmaceuticals, I… | $99.47 | 6.61B | -41% | +194% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | — | 46.13 | 89.73% | -101.19% | -106.41% | -129.46% | 96.50% | -45.05% | 0.03 | -9.33 | 4.41 | 3.92 | 0.29 | -2834.00% | 4583.00% | 241.00% | -1.89% | -1.09 | 58.61% | 0.09% | -2.70% | 0.09% | -30.13 | -49.60 | 30.48 | 13.65 |
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
- CEO
- Sven Ante Lundberg
- Employees
- 260
- Beta
- 1.06
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($21.74 ÷ —) − 1 = — (DCF, example).